NasdaqCM - Nasdaq Real Time Price USD

enVVeno Medical Corporation (NVNO)

Compare
3.2900 -0.0200 (-0.60%)
As of 10:53 AM EDT. Market Open.
Loading Chart for NVNO
DELL
  • Previous Close 3.3100
  • Open 3.2700
  • Bid 3.1700 x 100
  • Ask 3.3700 x 100
  • Day's Range 3.2450 - 3.3400
  • 52 Week Range 3.0120 - 6.9700
  • Volume 27,116
  • Avg. Volume 119,878
  • Market Cap (intraday) 57.693M
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3800
  • Earnings Date Nov 1, 2024 - Nov 6, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 18.00

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

www.envveno.com

31

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVNO

View More

Performance Overview: NVNO

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVNO
35.99%
S&P 500
20.07%

1-Year Return

NVNO
29.25%
S&P 500
37.45%

3-Year Return

NVNO
62.70%
S&P 500
24.36%

5-Year Return

NVNO
81.20%
S&P 500
87.98%

Compare To: NVNO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVNO

View More

Valuation Measures

Annual
As of 10/30/2024
  • Market Cap

    58.22M

  • Enterprise Value

    20.39M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.52

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.63%

  • Return on Equity (ttm)

    -61.28%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -20.6M

  • Diluted EPS (ttm)

    -1.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    39.07M

  • Total Debt/Equity (mrq)

    3.21%

  • Levered Free Cash Flow (ttm)

    -9.72M

Research Analysis: NVNO

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

18.00
18.00 Average
3.2900 Current
18.00 High
 

Company Insights: NVNO

People Also Watch